Antipsychotics (Neuroleptics) Class
The use of antipsychotics in clinical medicine focuses on treating the following disorders: psychotic symptoms of schizophrenia, bipolar disorders, and psychosis. At the present time the FDA has not approved antipsychotics for the treatment of dementia. Schizophrenia is the main disorder that employs the use of antipsychotics for patient treatment. The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines schizophrenia as a mental disturbance lasting for at least 6 months, including at least one month of two or more of the following symptoms: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms. The negative symptoms of schizophrenia include: inability to speak, lack of will, absence of pleasure, and lack of emotional expression. The positive symptoms of schizophrenia are: delusions, hallucinations, disorganized speech and catatonia. Other symptoms exhibited could be due to cognitive symptoms and/or mood symptoms. An example of cognitive symptoms would be attention deficit disorder and an example of mood symptoms would be hopelessness or suicidal tendencies.
Schizophrenia is the most chronic major mental illness disorder in people under the age of 65. The antipsychotic class of drugs offers some stability for these patients so they can function in a relationship, the workplace, and are able to tolerate psychotherapy. These antipsychotic compounds can be divided into seven different sub-groups based on their chemical structure. The classification is as follows:
- Phenothiazines - tricyclic amino-phenothiazine compounds
- Thioxanthenes - similar pharmacologically and chemical to phenothiazines
- Dibenzoxazepines - derived from the phenothiazines
- Dihydroindoles - structurally related to serotonin, melatonin, and the indole hallucinogens
- Butyrophenones - derived from pethidine-type analgesics, but lacking in morphine like activity
- Diphenylbutylpiperidines - similar to butyrophenones
- Benzamides
The antipsychotics are typically metabolized in the liver by the cytochrome 450 system, and reach steady state plasma concentrations in 2-10 days. The antipsychotics are lipophilic in nature and possess varying degrees of bioavailability. The antipsychotics possess half-lives that vary depending on the route of administration whether IM, IV, or oral.
The adverse effects of this class of medications varies from mild to life threatening depending on abuse. In general the adverse effects of these drugs are primarily non-neurologic in low doses and neurologic in high doses. Examples of non-neurologic adverse effects are as follows: cardiac effects causing abnormal EKGs which may lead to sudden death; orthostatic hypotension caused by adrenal blockade; hematologic effects due to transient leukopenia; anticholinergic effects such as dry mouth, blurred vision, nausea, and vomiting; and endocrine effects which cause blockade of dopamine receptors. The side effects due to the neurologic effects of antipsychotic compounds are the most serious in nature and are directly associated with the amount or potency of the antipsychotic agent taken. Examples of neurologic effects with these antipsychotics are as follows: extrapyramidal effects, Parkinsonism, neuroleptic malignant syndrome, epileptogenic effects, sedation, and central anticholinergic effects. Examples of extrapyramidal effects are involuntary muscle contraction of the neck and head. Examples of Parkinson effects are muscle stiffness, stooped posture, drooling, mask-like faces. Examples of Neuroleptic Malignant Syndrome are fluctuating levels of consciousness from agitation to stupor with autonomic dysregulation. This syndrome is the most toxic complication of neuroleptic use of antipsychotics. Neuroleptic Malignant Syndrome is also seen more frequently in males at any age. The mortality rate of this syndrome is 10-25% and should be carefully monitored. The antipsychotic class of drugs are mainly used for clinical treatment. Any toxic or adverse side effects are due to the dose of the medication and amount taken by the patient in preventing the symptoms of schizophrenia and not particularly due to the wanton drug-induced “high” that other types of drugs illicit. In general the serum or plasma concentrations of antipsychotic compounds do not correlate well with clinical signs and symptoms.
- Therapeutic monitoring
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Therapeutic levels: variable
Toxic levels: variable
Fatality levels: variable
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Serum
Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Depending upon the compound of interest, plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.
Stability
- Refrigeration: 7 days
- Frozen: 30 days
- Basalt RC (ed). Disposition of toxic drugs and chemicals in man, 7th ed. Foster City, CA: Biomedical Publications; 2004.
- Bell J. Methods for monitoring neuroleptic drugs. AACC Therapeutic Drug Monitoring and Toxicology. 1985;6:1-6.
- Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 24, Therapeutic Drugs III: Neuroleptics (Antipsychotics), 421-434; 2013.
- Balant-Gorgia A.E., Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera, 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.